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Introduction. Nipah virus (NiV) is a highly lethal zoonotic negative strain single stranded RNA Paramyxovirus belonging 
to the Henipa virus genus capable of causing severe neurological and respiratory infection with ability of devastating 
rapid morbidity and mortality around 89%. The most challenging part of NiV is that it is classified as BSL-4 agent for 
being deadly pathogen and there is no vaccination and treatment protocol recommended by WHO. Also, it exhibits 
normal flu like symptoms in the early stages and similar symptoms of Japanese encephalitis and dengue in the later 
stages, which reduce the chances of early diagnosis.  
Aim of the research. Firstly, The awareness of NiV to the medical world about the clinical and neurological features of 
this disease for the early diagnosis. Secondly, to bring forward the kerala (India)model of treatment and effective 
management strategies for the prevention of this disease  
Methods and materials. Nipah virus has identified in Malaysia, Bangladesh and India. It affect Kerala (India) during the 
period of May –June of 2018 and 19 peoples were affected. Patients showed clinical signs like headache, fever, 
vomiting, dizziness, impaired level of consciousness, reduced reflex, ARDS, seizures, segmental myoclonus, agitation, 
focal neurological signs, encephalitis, oculomotor palsy, cervical dystonia, facial paralysis, lower cranial nerve 
involvement, leading to coma and death. Out of 19, only 2 survived the deadly virus. The confirmatory tests used were 
real time PCR and ELISA. Treatment methods include wide range of broad spectrum antiviral drugs including Ribavirin, 
Favipiravir, Chloroquine…along with symptomatic treatment.  
Management strategies include special isolation ward, ambulance service, specialized medical team for Nipah patient 
with fully equipped PPE-kit and N-95 mask. Personal and hospital hygiene has been take special care, fumigation of the 
suspected areas. Community and contact surveillance of the suspected persons was done along with general public 
awareness about the disease and its precautions.  
Results. The main clinical manifestation of Nipah patients were fever (100%), vomiting (89%), ARDS (94%), seizure 
(63%), encephalitis (94%), agitation (52%), altered level of consciousness (89%). Along with clinical signs, diagnostic 
reports and isolation of NiV from CSF of the patient confirm its involvement of the brain.  
Conclusions. The statistical study of the clinical neurological symptoms and advanced analysis reports shows that the 
virus replication takes place in brain. The success of Kerala (India) model is early diagnosis and prevention of further 
spread of the infection.  
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Introduction. Neurofilaments are the intermediate filaments of nerve cells, also one of three classes of cytoskeletal 
polymers that comprise the nerve cell cytoskeleton. Neurofilaments are released into cerebrospinal fluid (CSF) heralding 
axonal injury as a result of neurological degenerative diseases, including multiple sclerosis (MS).  
Aim of the research. To determine the concentration of neurofilament light chain (NF-L) in CSF of patients with multiple 
sclerosis (IS) and demyelination, to evaluate its correlation with clinical and demographic parameters of the subjects.  
Materials and methods. Patients with diagnosis of MS or demyelinating disease ((n = 49), 32 (65%) females; mean age 
37 ± 9.7 years), admitted to Department of Neurology in 2018 February – November were included in the study. With the 
approval of the VULSK Commission of Ethics, demographic and clinical data of the subjects were collected 
retrospectively and levels of NF-L in CSF were measured by immunoassay. Subjects were divided into age groups (<29, 
30-39, > 40 yr. ), disability levels based on Expanded Disability Status Scale (EDSS) scores (<2.5, 3-3.5, > 4) and 
presence of oligoclonal bands (OCBs) in CSF (OCBs + / OCBs -). The correlation between collected data and the 
concentration of NF-L in CSF was analyzed. For data analysis Statistical Analysis SPSS software were used, the 
statistically significant differences between groups were considered at an adjusted p <0.05. 
Results. In the studied sample, the median concentration of NF-L in CSF was 705.3 pg / ml (min. 223.14pg / ml, max. 
5576.72pg / ml). Difference between mean values of NF-L among three age categories was statistically significant (p = 
0.01). The highest median value was observed in the youngest group (998.53pg / ml). NF-L levels in CSF of patients with 
IS diagnosis were significantly (t = 4.935, p <0.0005) different from those diagnosed with demyelination (medians 
